Evidence map›Paper›PMID 36530974›Full record

ReviewFrontiers in oncology2022

The role of microfibrillar-associated protein 2 in cancer.

Wanzhen Xu, Manfeng Wang, Yang Bai, Yong Chen, Xiaoshan Ma, Zhiqing Yang, Liyan Zhao, Yunqian Li

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Wanzhen XuDepartment of Neurosurgery, First Hospital of Jilin University, Changchun, China.
Manfeng WangDepartment of Geriatrics, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Yang BaiDepartment of Neurosurgery, First Hospital of Jilin University, Changchun, China.
Yong ChenDepartment of Neurosurgery, First Hospital of Jilin University, Changchun, China.
Xiaoshan MaDepartment of Neurosurgery, First Hospital of Jilin University, Changchun, China.
Zhiqing YangDepartment of Emergency Medicine, Binzhou People's Hospital, Binzhou, China.
Liyan ZhaoDepartment of Clinical Laboratory, Second Hospital of Jilin University, Changchun, China.
Yunqian LiDepartment of Neurosurgery, First Hospital of Jilin University, Changchun, China.
First Hospital of Jilin University · CNBinzhou People's Hospital · CNHarbin Medical University · CNJilin University · CNSecond Affiliated Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microfibrillar-associated protein 2 (MFAP2), a component of the extracellular matrix, is important in controlling growth factor signal transduction. Recent studies have shown that MFAP2, an effective prognostic molecule for various tumors, is associated with tumor occurrence and development and may be involved in remodeling the extracellular matrix and regulating proliferation, apoptosis, invasion, tumor cell metastasis, and tumor angiogenesis. However, MFAP2's specific mechanism in these tumor processes remains unclear. This article reviewed the possible mechanism of MFAP2 in tumorigenesis and progression and provided a reference for the clinical prognosis of patients with cancer and new therapeutic target discovery.

Indexed as

angiogenesisapoptosisextracellular matrix (ECM)invasionmetastasisMFAP2prognosisproliferation

Identifiers

PMID36530974
PMCPMC9748481
OpenAlexW4310995042

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.